Edgewise Therapeutics Inc

NASDAQ EWTX

Download Data

Edgewise Therapeutics Inc Sales to Fixed Assets Ratio 3 year CAGR for the quarter ending March 31, 2024

Edgewise Therapeutics Inc Sales to Fixed Assets Ratio 3 year CAGR is NA for the quarter ending March 31, 2024. Sales to fixed assets ratio measures the revenue generated by a company relative to its fixed assets, such as property, plant, and equipment. It is calculated by dividing the revenue by the net value of fixed assets. This ratio provides insights into the efficiency of the company's fixed assets in generating sales revenue. A higher sales to fixed assets ratio suggests better sales generation from fixed assets and efficient utilization of physical infrastructure. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Edgewise Therapeutics Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2023 was 0.00, a 0.00% change year over year.
  • Edgewise Therapeutics Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2022 was 0.00, a 0.00% change year over year.
  • Edgewise Therapeutics Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2021 was 0.00.
NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO Dr. Kevin Koch Ph.D.
IPO Date March 26, 2021
Location United States
Headquarters 3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees 92
Sector Healthcare
Industry Biotechnology
Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Similar companies

IPSC

Century Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

ACET

Adicet Bio Inc

NA

NA

VOR

Vor Biopharma Inc

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email